1. 2019 ESC Guidelines for the diagnosis and management of acutepulmonary embolism developed in collaboration with the EuropeanRespiratory Society (ERS) | European Heart Journal | Oxford Academic[İnternet]. [a.yer 10 Kasım 2022]. Erişim adresi: https://academic.oup.com/eurheartj/article/41/4/543/5556136
2. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with
intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-
1411. https://doi: 10.1056/NEJMoa1302097
3. Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm,
multicenter trial of ultrasound-facilitated, catheter-directed, low-dose
fibrinolysis for acute massive and submassive pulmonary embolism:
The SEATTLE II Study. JACC Cardiovasc Interv. 2015;8(10):1382-1392.
https://doi: 10.1016/j.jcin.2015.04.020
4. Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, FavrettoG, vd. Clinical features and short term outcomes of patients with acutepulmonary embolism. The Italian Pulmonary Embolism Registry (IPER).Thromb Res. 2012;130(6):847-52.
5. Piazza G. Advanced Management of Intermediate- and High-RiskPulmonary Embolism: JACC Focus Seminar. J Am Coll Cardiol.2020;76(18):2117-27.
6. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, RondinaMT, vd. Treatment of submassive pulmonary embolism with tenecteplaseor placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost JTH.2014;12(4):459-68.
7. Weinstein T, Deshwal H, Brosnahan SB. Advanced management ofintermediate-high risk pulmonary embolism. Crit Care Lond Engl.2021;25(1):311.
8. Kiser TH, Burnham EL, Clark B, Ho PM, Allen RR, Moss M, vd. Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism*.Crit Care Med. 2018;46(10):1617-25.
9. Tapson VF, Weinberg AS. Overview of Management of Intermediate- andHigh-Risk Pulmonary Embolism. Crit Care Clin. 2020;36(3):449-63.